Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to -$66.3 million.

  • Ptc Therapeutics' Cash from Operations rose 1388.59% to -$66.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $715.5 million, marking a year-over-year increase of 50200.99%. This contributed to the annual value of -$107.7 million for FY2024, which is 3202.29% up from last year.
  • Latest data reveals that Ptc Therapeutics reported Cash from Operations of -$66.3 million as of Q3 2025, which was up 1388.59% from -$58.3 million recorded in Q2 2025.
  • In the past 5 years, Ptc Therapeutics' Cash from Operations ranged from a high of $870.1 million in Q1 2025 and a low of -$166.0 million during Q4 2022
  • Moreover, its 5-year median value for Cash from Operations was -$55.2 million (2022), whereas its average is -$6.8 million.
  • As far as peak fluctuations go, Ptc Therapeutics' Cash from Operations tumbled by 43028.45% in 2024, and later skyrocketed by 112963.64% in 2025.
  • Ptc Therapeutics' Cash from Operations (Quarter) stood at -$68.8 million in 2021, then tumbled by 141.09% to -$166.0 million in 2022, then soared by 39.57% to -$100.3 million in 2023, then surged by 70.08% to -$30.0 million in 2024, then plummeted by 120.97% to -$66.3 million in 2025.
  • Its Cash from Operations was -$66.3 million in Q3 2025, compared to -$58.3 million in Q2 2025 and $870.1 million in Q1 2025.